8-chloro-1-cyclohexyl-N,N-dimethyl-4-oxo-4,5-dihydroimidazo-[1,5-a]quinoxaline-7-carboxamide | 1031369-69-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 8-chloro-1-cyclohexyl-N,N-dimethyl-4-oxo-4,5-dihydroimidazo-[1,5-a]quinoxaline-7-carboxamide
• 英文别名: 8-chloro-1-cyclohexyl-N,N-dimethyl-4-oxo-5H-imidazo[1,5-a]quinoxaline-7-carboxamide
• CAS: 1031369-69-3
• 化学式: C₁₉H₂₁ClN₄O₂
• 分子量: 372.854
• InChiKey: WMOSXRMMUWZZPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• QUINOXALINE DERIVATIVES
  申请人：Okada Makoto

  公开号：US20100048556A1

  公开（公告）日：2010-02-25

  The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R 1 and R 2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R 3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R 4 stands for hydrogen, hydroxy, alkyl or amino, R 5 and R 8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R 6 and R 7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR 9 or SO 2 R 9 , R 9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin- 1 -yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A 1 , A 2 and A 3 each independently stands for N or C.

  本发明揭示了具有PDE9抑制活性并可用作治疗排尿困难等的药物的喹啉衍生物或其盐，其由式（I）表示： 其中，R1和R2各自独立地表示氢、卤素、烷基、烷氧基、酰基、氨基等；R3表示烷基、芳基、饱和碳环族、饱和杂环族、酰基等；R4表示氢、羟基、烷基或氨基；R5和R8各自独立地表示氢、卤素、烷基、烯基、烷氧基、氰基或硝基；R6和R7各自独立地表示氢、卤素、烷基、烯基、炔基、烷氧基、氰基、氨基、碳环族、杂环族、COR9或SO2R9；R9表示氢、羟基、烷基、氨基、吡咯烷-1-基、哌啶-1-基、吡啶-1-基等；X表示S或O；A1、A2和A3各自独立地表示N或C。
• TREATING AGENT OF UROPATHY
  申请人：Gotanda Kotaro

  公开号：US20100113484A1

  公开（公告）日：2010-05-06

  Disclosed is a treating agent of overactive bladder syndrome, pollakiuria, urinary incontinence, dysuria in benign prostatic hyperplasia or urolithiasis, which comprises a compound having PDE9-inhibiting activity as the active ingredient.

  本发明涉及一种治疗过度活跃膀胱综合症、排尿频繁、尿失禁、良性前列腺增生或泌尿结石引起的排尿困难的治疗剂，其包含一种具有PDE9抑制活性的化合物作为活性成分。
• Substituted Imidazo[1,5-A]Quinoxalines As a PDE9 Inhibitor
  申请人：OKADA Makoto

  公开号：US20130225572A1

  公开（公告）日：2013-08-29

  The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R 1 and R 2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R 3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R 4 stands for hydrogen, hydroxy, alkyl or amino, R 5 and R 8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R 6 and R 7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR 9 or SO 2 R 9 , R 9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A 1 , A 2 and A 3 each independently stands for N or C.

  本发明揭示了具有PDE9抑制活性并可用作治疗排尿困难等的治疗剂的喹喔啉衍生物或其盐，其由公式(I)表示： 在公式中， R1和R2分别独立地表示氢、卤素、烷基、烷氧基、酰基、氨基等； R3表示烷基、芳基、饱和碳环基、饱和杂环基、酰基等； R4表示氢、羟基、烷基或氨基； R5和R8分别独立地表示氢、卤素、烷基、烯基、烷氧基、氰基或硝基； R6和R7分别独立地表示氢、卤素、烷基、烯基、炔基、烷氧基、氰基、氨基、碳环基、杂环基、COR9或SO2R9； R9表示氢、羟基、烷基、氨基、吡咯烷-1-基、哌啶-1-基、吡啶并嗪-1-基等； X表示S或O； A1、A2和A3分别独立地表示N或C。
• SUBSTITUTED IMIDAZO [1,5-a]QUINOXALINES AS A PDE9 INHIBITOR
  申请人：ASKA Pharmaceutical Co., Ltd.

  公开号：US20140336197A1

  公开（公告）日：2014-11-13

  The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R 1 and R 2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R 3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R 4 stands for hydrogen, hydroxy, alkyl or amino, R 5 and R 8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R 6 and R 7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR 9 or SO 2 R 9 , R 9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A 1 , A 2 and A 3 each independently stands for N or C.

  本发明公开了一种具有PDE9抑制活性并可用作治疗排尿困难等的奎诺克赖烷衍生物或其盐，其由式（I）表示，在该式中，R1和R2分别独立地代表氢、卤素、烷基、烷氧基、酰基、氨基等，R3代表烷基、芳基、饱和碳环族、饱和杂环族、酰基等，R4代表氢、羟基、烷基或氨基，R5和R8分别独立地代表氢、卤素、烷基、烯基、烷氧基、氰基或硝基，R6和R7分别独立地代表氢、卤素、烷基、烯基、炔基、烷氧基、氰基、氨基、碳环族、杂环族、COR9或SO2R9，R9代表氢、羟基、烷基、氨基、吡咯烷-1-基、哌啶-1-基、吡啶-1-基或类似物，X代表S或O，A1、A2和A3分别独立地代表N或C。
• THERAPEUTIC AGENT FOR URINARY TRACT DISEASE
  申请人：ASKA Pharmaceutical Co., Ltd.

  公开号：EP2123301A1

  公开（公告）日：2009-11-25

  Disclosed is a treating agent of overactive bladder syndrome, pollakiuria, urinary incontinence, dysuria in benign prostatic hyperplasia or urolithiasis, which comprises a compound having PDE9-inhibiting activity as the active ingredient.

  本发明公开了一种治疗膀胱过度活动症、花粉尿症、尿失禁、良性前列腺增生症排尿困难或尿路结石的药物，其活性成分包括一种具有 PDE9 抑制活性的化合物。